Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript pages. The focus appears to be on securing raw material supply, progressing clinical trials, and CAPEX spending rather than raising funds. The company has planned CAPEX of Rs. 270 crore over 18 months, funded likely from internal resources or existing mechanisms; no mention of raising funds externally. Research and development expenses and clinical trial costs are being managed within existing budgets without indications of new fundraising. Out-licensing of the molecule SUVN-502

Any current/future capex/capital investment/strategic investment?

Planned CAPEX of Rs. 270 crore, with Rs. 70 crore already spent. Additional Rs. 200 crore to be spent within the next 18 months (covering FY2019 and FY2020). A significant portion (Rs. 120 crore) is allocated for constructing a new block with occupational exposure levels required for new CRAMS projects. This CAPEX aims to meet future customer requirements and secure capacity for new and existing projects. The new block investment can potentially be recovered within 18 months if orders are secured quickly, although it could take 2-3 years. Efforts toward backward integration of raw materials ar

Future growth expectations in sales/revenue/volumes?

The core CRAMS business is in a growth phase and expected to grow around 10%-15% yearly. Growth depends heavily on the success and progression of clinical trials for molecules in development. There is an emphasis on transitioning molecules from Phase-1 to Phase-2 and later to Phase-3, with more activity expected from Phase-2 to Phase-3 over time. The number of molecules in development has been reduced, focusing on fewer but more promising candidates, leading to better traction and continuation through clinical phases. The company expects stability within next two to four quarters by securing r

Future growth expectations in earnings/operating earnings/profits/EPS?

The core CRAMS business is expected to grow in the range of 10% to 15% annually. Specialty segment growth is expected to be flat, with a variance of around 5% compared to the previous year. The CRAMS business growth depends heavily on the success of clinical trials, with progression from Phase-1 to Phase-2 currently active and Phase-2 to Phase-3 expected to pick up gradually. Raw material supply issues impacted revenue and profits in the short term but are expected to stabilize within two to three quarters. Overall earnings and profits face variability due to clinical trial outcomes and raw ma

Current/ Expected Orderbook/ Pending Orders?

As of the latest quarter discussed, Suven Life Sciences reports having a total of 116 CRAMS projects. Compared to the previous quarter (June 2018) and September 2017, there has been a net addition of 1 project recently, with 5 new projects added and 4 projects completed. The current base CRAMS business is expected to grow at a rate of 10% to 15% annually. Raw material shortages have caused some delays, but the company has secured raw material for shipments for the next two quarters. There might be potential delays after the next two quarters due to raw material sourcing challenges, but

Suven Life Sciences LtdQ2 FY19Healthcare Services

Suven Life Sciences Ltd Q2 FY19 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹308Market Cap: ₹9.5K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 4

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

The core CRAMS business is in a growth phase and expected to grow around 10%-15% yearly.
Growth depends heavily on the success and progression of clinical trials for molecules in development.
There is an emphasis on transitioning molecules from Phase-1 to Phase-2 and later to Phase-3, with more activity expected from Phase-2 to Phase-3 over time.
The number of molecules in development has been reduced, focusing on fewer but more promising candidates, leading to better traction and continuation through clinical phases.
The company expects stability within next two to four quarters by securing raw material supplies despite current shortages.
Specialty CRAMS business is expected to remain flat, growing around 5%.
Commercial product revenues are anticipated to be around Rs. 60-90 crore yearly.
Out-licensing opportunities depend on positive clinical trial data, potentially driving significant growth.

Margin guidance

Category 4

The core CRAMS business is expected to grow in the range of 10% to 15% annually.
Specialty segment growth is expected to be flat, with a variance of around 5% compared to the previous year.
The CRAMS business growth depends heavily on the success of clinical trials, with progression from Phase-1 to Phase-2 currently active and Phase-2 to Phase-3 expected to pick up gradually.
Raw material supply issues impacted revenue and profits in the short term but are expected to stabilize within two to three quarters.
Overall earnings and profits face variability due to clinical trial outcomes and raw material availability.
Consolidated financials may see pressure due to increasing clinical trial costs, but standalone business aims to maintain last year's earnings.
Out-licensing of successful molecules like SUVN-502 after positive clinical data can drive significant monetization, projected around Q3 of the following year (FY2020).

See what Suven Life Sciences Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript pages.
The focus appears to be on securing raw material supply, progressing clinical trials, and CAPEX spending rather than raising funds.
The company has planned CAPEX of Rs. 270 crore over 18 months, funded likely from internal resources or existing mechanisms; no mention of raising funds externally.
Research and development expenses and clinical trial costs are being managed within existing budgets without indications of new fundraising.
Out-licensing of the molecule SUVN-502 is considered a potential future monetization path, but no fundraising is planned related to this as of now.

Order book

As of the latest quarter discussed, Suven Life Sciences reports having a total of 116 CRAMS projects.
Compared to the previous quarter (June 2018) and September 2017, there has been a net addition of 1 project recently, with 5 new projects added and 4 projects completed.
The current base CRAMS business is expected to grow at a rate of 10% to 15% annually.
Raw material shortages have caused some delays, but the company has secured raw material for shipments for the next two quarters.
There might be potential delays after the next two quarters due to raw material sourcing challenges, but efforts for backward integration and alternate sourcing are underway.
The company is confident about maintaining a stable order flow, with expectations that disruptions due to raw material shortages will ease within three to four quarters.

See what Suven Life Sciences Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Planned CAPEX of Rs. 270 crore, with Rs. 70 crore already spent.
Additional Rs. 200 crore to be spent within the next 18 months (covering FY2019 and FY2020).
A significant portion (Rs. 120 crore) is allocated for constructing a new block with occupational exposure levels required for new CRAMS projects.
This CAPEX aims to meet future customer requirements and secure capacity for new and existing projects.
The new block investment can potentially be recovered within 18 months if orders are secured quickly, although it could take 2-3 years.
Efforts toward backward integration of raw materials are ongoing but are limited in scale due to cost-effectiveness.
Capacity utilization is currently at 100%.

Track Suven Life Sciences Ltd — get its next earnings analysis in your feed

How does Suven Life Sciences Ltd rank vs peers in Healthcare Services?

Pro feature

ThisSuven Life Sciences Ltd

Rev 3Mar 4

See where Suven Life Sciences Ltd sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Suven Life Sciences Ltd rank in Healthcare Services?

Compare Suven Life Sciences Ltd against every Healthcare Services company (Q2 FY19) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Suven Life Sciences Ltd's management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.
3B Blackbio DX Ltd (Q4 FY24)
41% increase). Key concall takeaways from 3B Blackbio DX Ltd's Q4 FY24 earnings call — and how it ranks against sector peers.

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →